TALS News and Press, Talaris Therapeutics Inc. From 06/26/23

2023-06-26 15:40:03 ET Navigating the world of penny stocks can often feel like a dance, full of rhythm, calculated movements, and unexpected twists. One of the popular styles in this domain is swing trading, a strategy where investors profit from the ‘swing’ or fluctuatio...

2023-06-22 13:21:19 ET Gainers: TRxADE HEALTH ( MEDS ) +56% . ShiftPixy ( PIXY ) +45% . Root ( ROOT ) +36% . VCI Global Limited ( VCIG ) +34% . Barfresh Food Group ( BRFH ) +27% . Oncolytics Biotech ( ONCY ) +23% . ...

2023-06-22 10:30:47 ET Palm Beach, FL – June 22, 2023 – FinancialNewsMedia.com News Commentary – Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is ...

2023-06-22 10:02:12 ET Gainers: TRxADE HEALTH ( MEDS ) +39% . Talaris Therapeutics ( TALS ) +25% . IGM Biosciences ( IGMS ) +11% . Predictive Oncology ( POAI ) +4% . Zymeworks ( ZYME ) +3% . Losers: Innovative Eyewear...

2023-06-22 07:55:31 ET Cell therapy company Talaris Therapeutics ( NASDAQ: TALS ) and privately-owned Tourmaline Bio announced an agreement on Thursday to combine in an all-stock transaction expected to close in Q4 2023. Per the terms, Tourmaline stockholders will receive shares...

Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) Combined company expected to have approximately $2 10 ...

2023-06-13 04:32:53 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased to $21.31B in Q1 2023, with Visa, McKesson, UnitedHealth, Elevance Health, and General Electric as the largest holdings. New stakes were established in Lululemon Athletica, Sherwin-Williams,...

2023-05-26 07:32:18 ET Talaris Therapeutics ( NASDAQ: TALS ) put its CFO in charge on Friday, replacing a CEO Scott Requadt, who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company. CFO Mary Kay Fenton has...

BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) , today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris’s Chief Financial...

Talaris Therapeutics ( NASDAQ: TALS ) is up 10% in premarket trading after announcing a corporate restructuring and starting a review of strategic alternatives. The cell therapy company is discontinuing two trials examining FCR001 for durable tolerance in living donor kidney trans...